title: Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.
authors.forename: N
authors.initials: N
authors.lastname: Vande Casteele
authors.forename: V
authors.initials: V
authors.lastname: Ballet
authors.forename: G
authors.initials: G
authors.lastname: Van Assche
authors.forename: P
authors.initials: P
authors.lastname: Rutgeerts
authors.forename: S
authors.initials: S
authors.lastname: Vermeire
authors.forename: A
authors.initials: A
authors.lastname: Gils
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000276:immunology*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000276:immunology*; D008297:Male; D011971:Receptors, Immunologic / Q000276:immunology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D011971:Receptors, Immunologic